Dr Reddy's Laboratories Malaysia wins at Healthcare Asia Pharma Awards 2026

The company’s programme expands patient access to cancer and chronic kidney disease therapies in Malaysia.

Dr Reddy's Laboratories Malaysia won the Initiative Award for Patient Support Program - Malaysia in the Healthcare Asia Pharma Awards 2026 for its Patient Assistance Program (PAP), which aims to improve access to treatment for patients with cancer and chronic kidney disease.

Access to innovative therapies remains a challenge for many patients due to high treatment costs. In response, Dr Reddy's Laboratories Malaysia introduced PAP to reduce financial barriers and ensure patients receive the medicines they need without additional costs.

The programme offers free-of-charge stock for selected therapies and ensures that hospitals and retail pharmacies apply no markup. This approach directs the benefit to patients instead of improving institutional margins. PAP covers high-value therapies such as enzalutamide, palbociclib, fulvestrant, and sevelamer, allowing eligible patients to continue treatment without financial strain.

Unlike common pricing strategies that rely on reducing drug prices, the programme uses a structured redemption system that delivers direct patient support. Through partnerships with healthcare providers and a coordinated logistics system, medicines reach patients efficiently whilst maintaining product value and market sustainability.

The initiative also integrates patient education and collaboration with healthcare professionals to support treatment adherence. By focusing on access and continuity of care, the programme helps patients stay on therapy and manage long-term conditions more effectively.

PAP also delivers measurable outcomes for the company and patients. Between May and December 2025, enzalutamide market share rose from 14% to 40%, supported by 236 redemptions. Palbociclib achieved an 11% market share from March to December 2025 with 204 redemptions despite strong price competition. Fulvestrant recorded 350 redemptions in the same period, with the private market expanding by 22%, whilst sevelamer recorded a 10% growth in the private sector.

The programme remains adaptable as patient needs and market conditions change, with continuous feedback allowing the company to refine eligibility criteria, redemption processes, and engagement with healthcare providers. The structure also allows new products to be added quickly, helping patients gain timely access to therapies as they become available.

The Healthcare Asia Pharma Awards shines a spotlight on the outstanding companies redefining pharmaceutical excellence in Asia. It lauds those who redefine the pharmaceutical landscape through innovative, unique initiatives that have significantly enhanced their businesses.

The Healthcare Asia Pharma Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be recognised for your organisation's innovative and unique initiatives that enhanced your business and remarkable contributions to the pharmaceutical industry, please contact Julie Anne Nuñez-Difuntorum at [email protected].